Business Description
Pharnext SA
ISIN : FR001400N1P4
Compare
Compare
Traded in other countries / regions
ALPHA.FranceP0X.GermanyPNEXF.USA IPO Date
2016-07-18Description
Pharnext SA is a biopharmaceutical company developing treatments targeting neurodegenerative diseases. The company also develop a Pleotherapy technology platform. Its product in the pipeline includes SYNGILITY; PXT3003 and PXT864. The company's only segment being research and development on new pharmaceutical therapies based on Pleotherapy.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Equity-to-Asset | -8.14 | |||||
| Debt-to-Equity | -0.77 | |||||
| Debt-to-EBITDA | -1.03 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -35.38 | |||||
| Beneish M-Score | -33.48 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -82.5 | |||||
| 3-Year EBITDA Growth Rate | 68.7 | |||||
| 3-Year Book Growth Rate | 64.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 21.27 | |||||
| 6-1 Month Momentum % | -77.78 | |||||
| 12-1 Month Momentum % | -99.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.41 | |||||
| Quick Ratio | 0.41 | |||||
| Days Sales Outstanding | 1551.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -290.7 | |||||
| Shareholder Yield % | -71166.67 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -238870 | |||||
| Net Margin % | -275180 | |||||
| FCF Margin % | -239130 | |||||
| ROA % | -522.79 | |||||
| ROIC % | -1677.66 | |||||
| 3-Year ROIIC % | 80.69 | |||||
| ROC (Joel Greenblatt) % | -9461.6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -1.02 | |||||
| EV-to-EBITDA | -1.03 | |||||
| EV-to-Forward-EBITDA | -2.07 | |||||
| EV-to-Revenue | 2615.8 | |||||
| EV-to-Forward-Revenue | 2.79 | |||||
| EV-to-FCF | -1.09 | |||||
| Earnings Yield (Greenblatt) % | -98.04 | |||||
| FCF Yield % | -797100 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pharnext SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.01 | ||
| EPS (TTM) (€) | -5000085.495 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.7 | ||
| 3-Year Sortino Ratio | 375.68 | ||
| Volatility % | 134.88 | ||
| 14-Day RSI | 21.27 | ||
| 14-Day ATR (€) | 0.000007 | ||
| 20-Day SMA (€) | 0.0002 | ||
| 12-1 Month Momentum % | -99.98 | ||
| 52-Week Range (€) | 0.0001 - 2 | ||
| Shares Outstanding (Mil) | 13.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pharnext SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pharnext SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Pharnext SA Frequently Asked Questions
What is Pharnext SA(XPAR:ALPHA)'s stock price today?
The current price of XPAR:ALPHA is €0.00. The 52 week high of XPAR:ALPHA is €2.00 and 52 week low is €0.00.
When is next earnings date of Pharnext SA(XPAR:ALPHA)?
The next earnings date of Pharnext SA(XPAR:ALPHA) is .
Does Pharnext SA(XPAR:ALPHA) pay dividends? If so, how much?
Pharnext SA(XPAR:ALPHA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers